China SXT Pharmaceuticals Reports H1 2024 Financials
Ticker: SXTC · Form: 6-K · Filed: Mar 28, 2025 · CIK: 1723980
| Field | Detail |
|---|---|
| Company | China Sxt Pharmaceuticals, Inc. (SXTC) |
| Form Type | 6-K |
| Filed Date | Mar 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 6-K, foreign-private-issuer
TL;DR
SXT just dropped their H1 2024 financials, check the 6-K for the numbers.
AI Summary
China SXT Pharmaceuticals, Inc. filed a Form 6-K on March 28, 2025, to report its unaudited condensed consolidated financial results for the six months ended September 30, 2024. The filing provides financial information for the period as required for foreign private issuers.
Why It Matters
This filing provides investors with updated financial performance data for China SXT Pharmaceuticals, Inc. for the first half of their fiscal year, allowing for assessment of the company's recent operational and financial health.
Risk Assessment
Risk Level: low — This is a routine financial disclosure filing (6-K) and does not contain new material events or significant financial changes.
Key Numbers
- H1 2024 — Financial Period (The filing covers the six months ended September 30, 2024.)
Key Players & Entities
- China SXT Pharmaceuticals, Inc. (company) — Filer of the report
- 0001013762-25-003583 (other) — Accession Number for the filing
- 20250328 (date) — Filing date
- September 30, 2024 (date) — End date of the financial reporting period
FAQ
What type of financial statements are being provided in this 6-K?
The filing provides "Unaudited Condensed Consolidated Financial Statements for the six months ended September 30, 2024."
What is the filing date of this Form 6-K?
This Form 6-K was filed on March 28, 2025.
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report the Company's financial results for the six months ended September 30, 2024.
Which annual report form does China SXT Pharmaceuticals, Inc. indicate it files?
The company indicates it files annual reports under cover of Form 20-F.
What is the principal executive office address of China SXT Pharmaceuticals, Inc.?
The principal executive office is located at 178 Taidong Rd North, Taizhou Jiangsu, China.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 28, 2025 regarding China SXT Pharmaceuticals, Inc. (SXTC).